Abstract: A method for predicting responsiveness to a HER2-directed therapy by assessing HER2 heterogeneity in a tumor includes contacting a sample of the tumor with a biomarker-specific reagent that specifically binds to HER2 protein and detecting HER2 protein in the sample, contacting the sample of the tumor with a first nucleic acid probe that specifically binds HER2 genomic DNA and detecting HER2 gene amplification status in the sample, contacting the sample of the tumor with a second nucleic acid probe that specifically binds HER2 RNA and detecting HER2 RNA status in the sample scoring the HER2 protein (IHC), HER2 gene (DISH), and HER2 RNA (RNA-ISH), predicting that the tumor is responsive to the HER2-directed therapy if the tumor reveals a first foci having a first score and a second score, in which the first score and the second score are not the same.

Abstract: The invention relates to nucleotides and amino acid sequences encoding Glucagon-like peptide-2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications.

Abstract: The invention relates to nucleotides and amino acid sequences encoding Glucagon-like peptide-2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications.

Abstract: The invention relates to nucleotides and amino acid sequences encoding Glucagon-like peptide-2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications.

Abstract: The invention relates to nucleotides and amino acid sequences encoding glucagon-like peptide 2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications.

Abstract: A novel, isolated EDG receptor that upon activation results in increased induction of IL-8 or NF-?B. Preferably, the EDG receptor is a human EDG-4 receptor, which has an amino acid sequence shown in FIGS. 16A and 16B, or a variant of these sequences having at least 91% sequence identity.

Abstract: The present invention is directed to nucleic acid sequence and amino acid sequences for mammalian EDG-7 receptor homologs, and particularly for human EDG-7 receptor homologs. The invention also provides methods for determining agonists and antagonsits for EDG-7 receptors in addition to assays, expression vectors, host cells and methods for treating disorders associated with abherrent expression or activity of EDG-7.

Abstract: A novel, isolated EDG receptor that upon activation results in increased induction of IL-8 or NF-&kgr;B. Preferably, the EDG receptor is a human EDG-4 receptor, which has an amino acid sequence shown in FIGS. 16A and 16B, or a variant of these sequences having at least 91% sequence identity.

Abstract: A lysolipid receptor, a human EDG-4 receptor, a method of identifying lysolipid receptors involved in inflammatory response and the lysolipid receptors so identified, and a method of identifying ligands which interact with such lysolipid receptors.

Abstract: The present invention is directed to nucleic acid sequence and amino acid sequences for mammalian EDG-7 receptor homologs, and particularly for human EDG-7 receptor homologs. The invention also provides methods for determining agonists and antagonsits for EDG-7 receptors in addition to assays, expression vectors, host cells and methods for treating disorders associated with abherrent expression or activity of EDG-7.

Abstract: The invention relates to nucleotides and amino acid sequences encoding glucagon-like peptide 2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications.

Abstract: The present invention describes a nucleic acid sequence and an amino acid sequence for novel mammalian, including human, EDG-5 receptor homologs.

Abstract: The present invention is directed to an isolated polynucleotide for novel G-Protein Coupled Receptors. More particularly, the present invention provides an isolated polynucleotide comprising the nucleic acid sequence SEQ ID NO: 1 or nucleic acid sequences that hybridize to SEQ ID NO: 1 or its complimentary strand having at least 40% sequence identity. Preferably, the hybridizing nucleic acid sequence should hybridize under stringent conditions and in particular have 85% sequence identity, more preferably 90% sequence identity, and most preferably 95% sequence identity.